Skip to main content
. 2016 Sep 29;115(10):1223–1233. doi: 10.1038/bjc.2016.313

Figure 2.

Figure 2

The MAPK p38 is necessary for the cytotoxic effect of EGFR-targeted therapies. (A) Left panel: western blot analysis of p38α expression in DiFi cells transduced with ShRNAs against p38α (Shp38α1 and Shp38α2) or against Luciferase (ShLuc; control). Equal loading is shown by tubulin. Right panel: SRB assays to assess cetuximab cytotoxicity in DiFi cells transduced with two different ShRNAs against p38α (Shp38α1 and Shp38α2). (B) SRB assays to assess the cytotoxicity of lapatinib (Lapa) or erlotinib (Erlo); (C) alone or in combination with 5 μM SB202190 (SB, p38 inhibitor) in DiFi cells. NT, not treated. *P<0.05, **P<0.01, ***P<0.001. (D) Left panel: western blot analysis of p38α expression in LIM1215 cells transduced with ShRNAs against p38α (Shp38α1 and Shp38α2) or against Luciferase (ShLuc; control). Equal loading is shown by tubulin. Right panel: SRB assays to assess cetuximab cytotoxicity in LIM1215 cells transduced with ShRNA against p38α. (E) SRB assays to assess the cytotoxicity of cetuximab alone or in combination with 5 μM SB202190 (SB, p38 inhibitor) in LIM1215 cells.